Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of rVSV-ZEBOV-GP (V920 Ebola Vaccine) Consistency Lots and High Dose in Healthy Adults
2015-001658-14Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (5 arms), sponsored by Merck & Co. Primary endpoint: Anti-ZEBOV GP-ELISA GMT at Day 28. Started Jul 2015; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2015-001658-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001658-14.